Page last updated: 2024-08-16

sibutramine and orlistat

sibutramine has been researched along with orlistat in 213 studies

Research

Studies (213)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	15 (7.04)	18.2507
2000's	157 (73.71)	29.6817
2010's	40 (18.78)	24.3611
2020's	1 (0.47)	2.80

Authors

Authors	Studies
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Proietto, J	1
Borrell, L; Foreyt, JP; Haddock, CK; Poston, WS	1
Rissanen, A	1
Aronne, LJ	3
Schusdziarra, V	1
Lean, M	1
De Leeuw, IH; Peiffer, FW; Van Gaal, LF	1
Williams, G	1
Féry, F; Watrin, I	1
Blackburn, GL; Chan, S; Greenberg, I	1
Collazo-Clavell, ML	1
Apovian, CM	1
Richter, WO	1
Suter, PM; Vetter, W	1
Plauth, M; Schmidt, H	1
Agrawal, M; Diamond, L; Worzniak, M	1
Berke, EM; Morden, NE	1
Finer, N	2
Birkeland, KI; Tonstad, S	1
Arnold, ME; Berkowitz, RI; Sarwer, DB; Steinberg, CM; Wadden, TA; Womble, LG	1
Ballmer, PE; Imoberdorf, R	1
Weiss, D	1
Fuente Martinez, M; Jacqué, M; Keipes, M; Klees, J; Kuffer, V; Mersch, L; Nicolay, L	1
Czupryniak, L; Drzewoski, J	1
Blackburn, GL; Fernstrom, MH	1
Hauner, H	3
Mooradian, AD	1
Vettor, R	1
Federspil, G; Pagano, C; Vettor, R	1
García-Luna, PP; Soto Moreno, AM	1
Clark, K; Coleman, E; Donnelly, JE; Foreyt, J; Jakicic, JM; Melanson, E; Volek, J; Volpe, SL	1
Moyad, MA	1
BascilTutuncu, N; Gokcel, A; Gumurdulu, Y; Guvener, N; Karakose, H; Melek Ertorer, E; Tanaci, N	1
Boguszewski, CL; De Almeida, SM; Niclewicz, PA; Radominski, RB; Rodrigues, AM; Suplicy, Hde L	1
Hidalgo Mora, JJ; Martínez-Mir, I; Palop Larrea, V; Sempere I Verdú, E	1
Mustajoki, P	1
Phelan, S; Wadden, TA	1
Verspohl, EJ	1
Sanders, TA; Taylor, D; Werneke, U	1
Anghelescu, I; Klawe, C; Szegedi, A	1
Patten, SB	1
Garcia-Robles, R; Moreno, B; Ruilope, LM	1
Fernstrom, JD; Fernstrom, MH	1
Hanif, MW; Kumar, S	1
Carruba, MO; Nisoli, E	1
Ernest, P; Scheen, AJ	1
Gura, T	1
Chan, JC; Leung, WY; Thomas, GN; Tomlinson, B	1
Haynes, WG	1
Vastag, B	1
Wirth, A	2
Weigle, DS	1
Kumar, S; Peter, P	1
Lau, DC; Li, SK; Padwal, R	3
Karaoglanoglu, M; Kilic, FB; Nazligul, Y; Sabuncu, T; Ucar, E	1
Annan, F; Bunn, E; Connor, H; Frost, G; McGough, N; Sarwar, T; Thomas, B	1
Engeli, S	1
Heufelder, AE	1
Keller, U; Stöckli, R	1
Aronne, LJ; Thearle, M	1
Hill, JO; Wyatt, HR	1
Al Daghri, N; Barnett, AH; Chetty, R; Field, A; Hanif, W; Kumar, S; McTernan, PG; Valsamakis, G	1
Aydin, N; Dağar, A; Duman, C; Karasakal, M; Kaya, A; Topsever, P	1
Aucott, L; Avenell, A; Broom, J; Brown, TJ; Campbell, MK; Grant, AM; Jung, RT; Poobalan, A; Smith, WC; Stearns, SC	1
Avenell, A; Gregg, E; Kim, C; Lau, J; Norris, SL; Schmid, CH; Zhang, X	1
Ludvik, B; Tripp, B	1
Altunbas, H; Balci, MK; Cakir, M; Karayalcin, U; Sari, R	1
Halford, JC	2
Li, Z; Maggard, M; Maglione, M; Mojica, WA; Morton, SC; Shekelle, PG; Shugarman, L; Solomon, V; Suttorp, M; Tu, W	1
Svendsen, OL	1
Joyal, SV	1
Arterburn, D	2
Ballaux, D; Mertens, I; Van Gaal, L; Verkade, HJ	1
Ciccarelli, L; Cicero, AF; Derosa, G; Fogari, R; Murdolo, G	1
Aydin, N; Dağar, A; Ekmekcioglu, C; Filiz, M; Kaya, A; Kilinç, E; Oztürk, A; Topsever, P	1
Ryan, DH; Stewart, TM	1
Bertone, G; Ciccarelli, L; Cicero, AF; Derosa, G; Fogari, E; Fogari, R; Murdolo, G; Piccinni, MN	1
Avenell, A; Gregg, E; Lau, J; Norris, SL; Schmid, CH; Zhang, X	1
Klein, S	1
McLoughlin, C	1
Doggrell, SA	2
Bérubé-Parent, S; Chaput, JP; Tremblay, A	1
Astorga Jiménez, R; Pereira Cunill, JL	1
Kennedy, RL; Khoo, EY	1
Arterburn, D; DeLaet, D; Flum, D	1
Steinbeck, K	1
Mathys, M	1
Padwal, RS	1
Molnár, D	1
Astrup, AV; Breum, L; Bruun, JM; Svendsen, OL; Toubro, S	1
Cheskin, LJ; Sidhaye, A	1
Blackburn, GL; Waltman, BA	1
Clark, JM	1
Hamann, A	2
Behn, A; Ur, E	1
Halpern, A; Mancini, MC	1
Dixon, JB	1
Caterson, ID; Finer, N	1
Pi-Sunyer, FX	1
Chaput, JP; Tremblay, A	1
Cannon, E; Lundquist, LM; Sirimaturos, M	1
Boss, O; Hofbauer, KG; Nicholson, JR	1
Candil, SD; Martínez, JJ; Ruiz, FA	1
Bonanomi, G; Di Caro, S; Fernstrom, MH; Hamad, GG; Schauer, PR	1
Hofbauer, KG; Nicholson, JR	1
Beermann, B; Dahlin, A	1
Majumdar, SR; Padwal, RS	1
Rotthoff, T; Scherbaum, WA	1
Chaput, JP; St-Pierre, S; Tremblay, A	1
Baskal, N; Cesur, M; Cin, MO; Erdogan, MF; Gursoy, A	1
Aronne, LJ; Lee, M	1
Alonso Franch, M; Dalmau Serra, J; Gómez López, L; Martínez Costa, C; Sierra Salinas, C	1
Formiguera, X; Sierra, A	1
Etminan, M; Kezouh, A; Levine, M; Padwal, R	1
Car, J; Majeed, A; Patel, H; Srishanmuganathan, J	1
Bray, GA; Ryan, DH	1
Elisaf, MS; Filippatos, TD; Kiortsis, DN; Konitsiotis, S; Tsouli, S	1
Elfhag, K; Finer, N; Rössner, S	1
Malone, M	1
Desilets, AR; Dunican, KC; Montalbano, JK	1
Chien, HC; Chou, P; Lee, WJ; Lin, WY; Liou, TH; Wu, CH	1
Addy, C; Amatruda, JM; Astrup, A; Erondu, N; Gantz, I; Gottesdiener, KM; Haynes, WG; Heymsfield, SB; Kaufman, KD; Lu, K; Mallick, M; Musser, B; Proietto, J; Rissannen, AM; Tonstad, S; Toubro, S	1
Toubro, S	1
Gargallo, M; Isabel Millán, A; Moreno, B; Rubio, MA	1
Boucher, JL; Bowman, JD; Caplan, W; Crain, AL; Franz, MJ; Histon, T; Pronk, NP; VanWormer, JJ	1
Dicembrini, I; Mannucci, E; Rotella, CM; Rotella, F	1
Zieba, R	1
Käser, L; Kolyvanos, NU; Suter, PM; Vetter, W	1
Bodary, PF; Eitzman, DT; Iglay, HB	1
Perrio, MJ; Shakir, SA; Wilton, LV	1
Johansson, K; Neovius, M; Rössner, S	1
Kaila, B; Raman, M	1
Nau, JY	1
Al-Zaman, Y; Aylwin, S	1
Gratzer, TW; Horvath, K; Jeitler, K; Siebenhofer, A; Siering, U; Skipka, G; Stich, AK	1
Aronne, LJ; Neff, LM	1
Bischoff, A	1
Barnett, A; Rahim, A; Samat, A	1
Pagotto, U; Pasquali, R; Vanuzzo, D; Vicennati, V	1
Narbro, K; Neovius, M	1
Bruty, H; Powers, PS	1
Fabbrini, E; Klein, S	1
Aronne, LJ; Davis, SN; Foster, GD; Pagotto, U	1
Idelevich, E; Kirch, W; Schindler, C	1
Höcht, C; Mayer, MA; Puyó, A; Taira, CA	1
Choussein, S; Daskalopoulou, SS; Frangos, CC; Makri, AA; Petridou, ET	1
Beil, T; Lutz, K; O'Connor, E; Whitlock, E; Williams, S	1
DeSantis, SM; Johansson, K; Neovius, K; Neovius, M; Rössner, S	1
Coutinho, W	1
Barzi, F; Baur, LA; Chalmers, J; Czernichow, S; Greenfield, JR; Huxley, RR; Lee, CM; Woodward, M	1
Berghold, A; Horvath, K; Jeitler, K; Matyas, E; Pignitter, N; Siebenhofer, A; Siering, U; Stich, AK	1
Fernstrom, MH	1
Wadden, TA	1
Hansen, BC	1
Chang, CS; Kuo, HC; Wu, CH; Yu, C	1
Niswender, KD; Robinson, JR	1
Hsia, Y; Tomsic, T; Viner, RM; Wong, IC	1
Hsia, Y; Neubert, A; Viner, RM; Wong, IC	1
Amundsen, MO; Berg, C; Engdahl, B; Nordeng, H	1
Johansson, K; Neovius, K; Neovius, M; Rössner, S; Sundström, J	1
Beil, TL; Lutz, KW; O'Connor, EA; Whitlock, EP; Williams, SB	1
Kaplan, LM	1
Rao, G	1
Westly, E	1
Grief, SN; Miranda, RL	1
Delkos, D; Dinas, K; Kalaitzakis, E; Kandaraki, EA; Katsikis, I; Koiou, E; Panidis, D; Tziomalos, K	1
Madsbad, S	1
Hainer, V	1
Delkos, D; Kalaitzakis, E; Kandaraki, EA; Katsikis, I; Koiou, E; Panidis, D; Tziomalos, K; Vosnakis, C	1
Endevelt, R; Hemo, B; Porath, A; Shai, I; Stampfer, MJ	1
Barendregt, JJ; Forster, M; Veerman, JL; Vos, T	1
Ahmed, S; Ghaly, I	1
Abrams, K; Ara, R; Cooper, N; Davies, MJ; Dunkley, A; Gray, LJ; Khunti, K; Sutton, A; Warren, FC	1
Abrams, K; Ara, R; Blake, L; Cooper, N; Crowther, M; Davies, M; Dunkley, A; Gray, L; Hernández, M; Jackson, R; Khunti, K; Rees, A; Stevenson, M; Sutton, A; Warren, F	1
Bedros, JR; Medvegy, M; Pados, G; Simonyi, G	1
Kachowski, L; Over, DR; Qiu, K	1
Armstrong, SC; Dolinsky, DH; Kinra, S	1
Chan, LS; Kaptein, EM; Kaptein, JS	1
Kautzky-Willer, A; Lemmens-Gruber, R	1
Ahn, HY; Hwang, IC; Kim, KK; Oh, SW; Suh, HS	1
Berghold, A; Horvath, K; Jeitler, K; Semlitsch, T; Siebenhofer, A; Siering, U	1
Peña, S; Pérez-Álvarez, JA; Sayas-Barberá, E; Sendra, E; Trigueros, L; Ugidos, AV	1
Block, JP; Brennan, TA; Carpenter, DP; Choudhry, NK; Fischer, MA; Matlin, OS; Shrank, WH; Tong, AY	1
Al-Tahami, BA; Awang, SA; Bee, YT; Ismail, AA; Rasool, AH; Salha Wan Abdul Rani, WR; Sanip, Z	1
Baretić, M	1
Ahn, HY; Hwang, IC; Kim, KA; Kim, KK; Ko, KD; Park, JY; Suh, HS	1
Hwang, IC; Kim, KK; Ko, KD; Suh, HS	1
Batterham, RL; Bhaskaran, K; Douglas, IJ; Smeeth, L	1
Batterham, R; Bhaskaran, K; Douglas, I; Hayes, JF; Smeeth, L	1
Berghold, A; Horvath, K; Jeitler, K; Meschik, J; Posch, N; Semlitsch, T; Siebenhofer, A	1
Atkinson, G; Baur, L; Corpeleijn, E; Ells, LJ; Finer, N; Mead, E; Metzendorf, MI; O'Malley, C; Richter, B	1
Lee, JW; Park, S; Shin, HY	1
Ahmed, AT; Almasri, J; Alsawas, M; Asi, N; Farah, W; Mohammed, K; Murad, MH; Prokop, LJ; Rajjo, T	1
Al-Safi Ismail, AA; Al-Tahami, BAM; Rasool, AHG; Sanip, Z; Shihabudin, TMT; Singh, TSP; Yusoff, Z	1
Boger, BS; Canuto, MC; Cercato, C; de Melo, ME; Mancini, MC; Noriega, PEP; Queiroz, NL; Stumpf, MAM	1

Reviews

133 review(s) available for sibutramine and orlistat

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016
Challenges in obesity management. Southern medical journal, 1998, Volume: 91, Issue:8 Topics: 1-Naphthylamine; Adrenergic beta-Agonists; Appetite Depressants; Behavior Therapy; Caffeine; Cyclobutanes; Diethylpropion; Ephedrine; Fenfluramine; Fluoxetine; Humans; Lactones; Leptin; Lipase; Obesity; Orlistat; Phentermine; Proteins; Sertraline	1998
Pharmacological intervention: the antiobesity approach. European journal of clinical investigation, 1998, Volume: 28 Suppl 2 Topics: Appetite Depressants; Blood Glucose; Controlled Clinical Trials as Topic; Cyclobutanes; Dexfenfluramine; Diabetes Mellitus, Type 2; Humans; Lactones; Longitudinal Studies; Obesity; Orlistat; Weight Loss	1998
Modern medical management of obesity: the role of pharmaceutical intervention. Journal of the American Dietetic Association, 1998, Volume: 98, Issue:10 Suppl 2 Topics: Appetite Depressants; Chronic Disease; Cyclobutanes; Enzyme Inhibitors; Humans; Lactones; Lipase; Obesity; Orlistat	1998
[What is the role of drugs in therapy of obesity?]. Wiener medizinische Wochenschrift (1946), 1998, Volume: 148, Issue:17 Topics: Appetite Depressants; Cyclobutanes; Enzyme Inhibitors; Humans; Lactones; Obesity; Orlistat; Treatment Outcome	1998
Cutting fat absorption to halt weight gain. The Practitioner, 1998, Volume: 242, Issue:1593 Topics: Anti-Obesity Agents; Cyclobutanes; Diet, Fat-Restricted; Family Practice; Humans; Intestinal Absorption; Lactones; Obesity; Orlistat; Weight Gain	1998
Obesity and type 2 diabetes: a conflict of interests? International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 1999, Volume: 23 Suppl 7 Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Type 2; Humans; Lactones; Obesity; Orlistat; Weight Loss	1999
[New treatments for obesity]. Revue medicale de Bruxelles, 1999, Volume: 20, Issue:4 Topics: Amphetamines; Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Enzyme Inhibitors; Humans; Lactones; Lipase; Molecular Biology; Obesity; Orlistat; Safety; Selective Serotonin Reuptake Inhibitors	1999
Nonpharmacologic and pharmacologic management of weight gain. The Journal of clinical psychiatry, 1999, Volume: 60 Suppl 21 Topics: Anti-Obesity Agents; Appetite Depressants; Behavior Therapy; Cyclobutanes; Diet, Reducing; Energy Intake; Exercise; Humans; Lactones; Obesity; Obesity, Morbid; Orlistat; Psychotropic Drugs; Self-Help Groups; Weight Gain	1999
Safe and effective management of the obese patient. Mayo Clinic proceedings, 1999, Volume: 74, Issue:12 Topics: Anti-Obesity Agents; Appetite Depressants; Cognitive Behavioral Therapy; Cyclobutanes; Exercise; Gastric Bypass; Humans; Lactones; Lipase; Obesity; Obesity, Morbid; Orlistat; Selective Serotonin Reuptake Inhibitors; Weight Loss	1999
The use of pharmacologic agents in the treatment of the obese patient. The Journal of the American Osteopathic Association, 1999, Volume: 99, Issue:10 Su Pt 2 Topics: Anti-Obesity Agents; Body Mass Index; Cyclobutanes; Female; Follow-Up Studies; Humans; Lactones; Male; Obesity; Orlistat; Phentermine; Weight Loss	1999
[Drug therapy of obesity. Strategies for general practice]. Praxis, 2000, Mar-30, Volume: 89, Issue:14 Topics: Appetite Depressants; Combined Modality Therapy; Contraindications; Cyclobutanes; Family Practice; Humans; Lactones; Life Style; Obesity; Orlistat; Switzerland	2000
Managing obesity like any other chronic condition. Long-term therapy may reduce comorbidity as well. Postgraduate medicine, 2000, Volume: 108, Issue:1 Topics: Anti-Obesity Agents; Appetite Depressants; Chronic Disease; Contraindications; Cyclobutanes; Humans; Lactones; Obesity; Orlistat	2000
Medical management of obesity. American family physician, 2000, Jul-15, Volume: 62, Issue:2 Topics: Algorithms; Anti-Obesity Agents; Appetite Depressants; Basal Metabolism; Body Mass Index; Cyclobutanes; Decision Trees; Diagnosis, Differential; Energy Intake; Exercise; Feeding Behavior; Humans; Lactones; Life Style; Lipase; Obesity; Orlistat; Risk Factors	2000
[The obesity epidemics--do diet pills have a place in the treatment?]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2000, Jun-30, Volume: 120, Issue:17 Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Fenfluramine; Humans; Lactones; Leptin; Obesity; Obesity, Morbid; Orlistat; Phentermine; Selective Serotonin Reuptake Inhibitors; Weight Loss	2000
[Obesity: principles of drug therapy]. Therapeutische Umschau. Revue therapeutique, 2000, Volume: 57, Issue:8 Topics: Aminorex; Anti-Obesity Agents; Appetite Depressants; Chronic Disease; Combined Modality Therapy; Cyclobutanes; Dexfenfluramine; Diet, Reducing; Drug and Narcotic Control; Germany; Heart Valve Diseases; Humans; Hypertension, Pulmonary; Lactones; Obesity; Orlistat; Phentermine	2000
How to help your patients lose weight: current therapy for obesity. Cleveland Clinic journal of medicine, 2000, Volume: 67, Issue:10 Topics: Anti-Obesity Agents; Antidepressive Agents; Appetite Depressants; Behavior Therapy; Chronic Disease; Cyclobutanes; Diet, Reducing; Exercise; Gastric Bypass; Humans; Lactones; Obesity; Orlistat; Prevalence; Randomized Controlled Trials as Topic; United States	2000
[SEEDO'2000 consensus for the evaluation of overweight and obesity and the establishment of criteria for therapeutic intervention. Sociedad Española para el Estudio de la Obesidad]. Medicina clinica, 2000, Nov-04, Volume: 115, Issue:15 Topics: Adolescent; Adult; Age Factors; Aged; Anti-Obesity Agents; Appetite Depressants; Biliopancreatic Diversion; Body Weight; Child; Cross-Sectional Studies; Cyclobutanes; Diet; Exercise; Female; Gastric Bypass; Gastroplasty; Health Education; Humans; Lactones; Life Style; Male; Middle Aged; Nutritional Physiological Phenomena; Obesity; Obesity, Morbid; Orlistat; Primary Prevention; Psychotherapy; Risk Factors; Sex Factors; Spain	2000
Treating obesity: a new target for prevention of coronary heart disease. Progress in cardiovascular nursing, 2001,Summer, Volume: 16, Issue:3 Topics: Anti-Obesity Agents; Coronary Disease; Cyclobutanes; Humans; Lactones; Obesity; Orlistat; Randomized Controlled Trials as Topic	2001
Current pharmacological approaches to the treatment of obesity. International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 2001, Volume: 25 Suppl 1 Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypertension; Lactones; Obesity; Orlistat; Risk Factors; Treatment Outcome	2001
Obesity: a rational target for managing diabetes mellitus. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 2001, Volume: 11 Suppl A Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Diabetes Mellitus, Type 2; Humans; Lactones; Obesity; Orlistat; Prevalence; Weight Loss	2001
Obesity: a new paradigm in endocrinology. Eating and weight disorders : EWD, 2001, Volume: 6, Issue:3 Suppl Topics: Adipose Tissue; Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Endocrinology; Humans; Lactones; Models, Biological; Molecular Biology; Neuropeptides; Obesity; Orlistat	2001
The advances on the knowledge base of obesity and future therapeutic directions. Eating and weight disorders : EWD, 2001, Volume: 6, Issue:3 Suppl Topics: Anti-Obesity Agents; Cyclobutanes; Energy Metabolism; Humans; Lactones; Neuropeptides; Obesity; Orlistat	2001
American College of Sports Medicine position stand. Appropriate intervention strategies for weight loss and prevention of weight regain for adults. Medicine and science in sports and exercise, 2001, Volume: 33, Issue:12 Topics: Adult; Body Mass Index; Cyclobutanes; Diet Therapy; Dietary Fats; Energy Intake; Exercise Therapy; Health Behavior; Humans; Lactones; Life Style; Obesity; Orlistat; Physical Endurance; Secondary Prevention; Weight Gain; Weight Lifting; Weight Loss	2001
Current methods used for defining, measuring, and treating obesity. Seminars in urologic oncology, 2001, Volume: 19, Issue:4 Topics: Absorptiometry, Photon; Anti-Obesity Agents; Body Composition; Body Constitution; Body Mass Index; Cyclobutanes; Diet, Reducing; Exercise; Humans; Lactones; Life Style; Obesity; Orlistat; Prevalence	2001
Combining behavioral and pharmacological treatments for obesity. Obesity research, 2002, Volume: 10, Issue:6 Topics: Anti-Obesity Agents; Appetite Depressants; Behavior Therapy; Combined Modality Therapy; Cyclobutanes; Diet; Exercise; Humans; Lactones; Life Style; Obesity; Orlistat; Weight Loss	2002
[Weight reduction. Antiobesity drug treatment in type-2 diabetics]. Pharmazie in unserer Zeit, 2002, Volume: 31, Issue:3 Topics: Animals; Anti-Obesity Agents; Appetite Depressants; Clinical Trials as Topic; Cyclobutanes; Diabetes Mellitus, Type 2; Humans; Lactones; Obesity; Orlistat; Weight Loss	2002
Options for pharmacological management of obesity in patients treated with atypical antipsychotics. International clinical psychopharmacology, 2002, Volume: 17, Issue:4 Topics: Amantadine; Antipsychotic Agents; Cimetidine; Cyclobutanes; Fluoxetine; Fructose; Humans; Lactones; Metformin; Nizatidine; Obesity; Orlistat; Topiramate; Weight Gain	2002
Add-on combination and maintenance treatment: case series of five obese patients with different eating behavior. Journal of clinical psychopharmacology, 2002, Volume: 22, Issue:5 Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Chemotherapy, Adjuvant; Cyclobutanes; Feeding Behavior; Female; Fructose; Humans; Lactones; Male; Middle Aged; Obesity; Orlistat; Topiramate	2002
Major depressive episodes and diet pills. Expert opinion on pharmacotherapy, 2002, Volume: 3, Issue:10 Topics: Anti-Obesity Agents; Appetite Depressants; Central Nervous System Stimulants; Cyclobutanes; Depressive Disorder; Feeding Behavior; Humans; Lactones; Orlistat; Serotonin Agents	2002
Obesity, cardiovascular risk and pharmacotherapy. Blood pressure, 2002, Volume: 11, Issue:5 Topics: Anti-Obesity Agents; Appetite Depressants; Cardiovascular Diseases; Cyclobutanes; Humans; Lactones; Obesity; Orlistat; Risk Factors	2002
Pharmacotherapy of obesity. Best practice & research. Clinical endocrinology & metabolism, 2002, Volume: 16, Issue:4 Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Diabetes Mellitus, Type 2; History, 20th Century; Humans; Lactones; Obesity; Orlistat; Weight Loss	2002
The new role of pharmacotherapy for weight reduction in obesity. International journal of clinical practice, 2002, Volume: 56, Issue:9 Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Humans; Lactones; Life Style; Obesity; Orlistat; Weight Loss	2002
Pharmacological management of obesity. Expert opinion on pharmacotherapy, 2002, Volume: 3, Issue:12 Topics: Anti-Obesity Agents; Appetite Depressants; Clinical Trials as Topic; Cyclobutanes; Humans; Lactones; Methylcellulose; Obesity; Orlistat; Phentermine	2002
New pharmacological tools for obesity. Journal of endocrinological investigation, 2002, Volume: 25, Issue:10 Topics: Animals; Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Drug Industry; Humans; Lactones; Obesity; Orlistat	2002
New antiobesity agents in type 2 diabetes: overview of clinical trials with sibutramine and orlistat. Diabetes & metabolism, 2002, Volume: 28, Issue:6 Pt 1 Topics: Anti-Obesity Agents; Appetite Depressants; Blood Glucose; Clinical Trials as Topic; Controlled Clinical Trials as Topic; Cyclobutanes; Diabetes Mellitus; Diabetes Mellitus, Type 2; Humans; Lactones; Obesity; Orlistat; Weight Loss	2002
Weight management and current options in pharmacotherapy: orlistat and sibutramine. Clinical therapeutics, 2003, Volume: 25, Issue:1 Topics: Anti-Obesity Agents; Body Mass Index; Cyclobutanes; Dose-Response Relationship, Drug; Drug Interactions; Humans; Lactones; Obesity; Orlistat; Randomized Controlled Trials as Topic; Weight Loss	2003
Medical management of obesity: a clinical imperative? Current diabetes reports, 2003, Volume: 3, Issue:1 Topics: Anti-Obesity Agents; Cyclobutanes; Diabetes Mellitus, Type 2; Diet; Exercise; Humans; Lactones; Life Style; Obesity; Orlistat	2003
[Weight loss via drug therapy]. Der Internist, 2003, Volume: 44, Issue:3 Topics: Anti-Obesity Agents; Appetite Depressants; Body Mass Index; Clinical Trials as Topic; Combined Modality Therapy; Cyclobutanes; Humans; Lactones; Obesity; Orlistat; Practice Guidelines as Topic; Treatment Outcome	2003
Pharmacological therapy of obesity: past, present, and future. The Journal of clinical endocrinology and metabolism, 2003, Volume: 88, Issue:6 Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Endocrinology; Humans; Lactones; Obesity; Orlistat	2003
Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 2003, Volume: 27, Issue:12 Topics: Anti-Obesity Agents; Cyclobutanes; Humans; Lactones; Obesity; Orlistat; Randomized Controlled Trials as Topic	2003
Long-term pharmacotherapy for obesity and overweight. The Cochrane database of systematic reviews, 2003, Issue:4 Topics: Anti-Obesity Agents; Appetite Depressants; Body Weight; Cyclobutanes; Humans; Lactones; Obesity; Orlistat; Randomized Controlled Trials as Topic; Weight Loss	2003
[New therapeutic options in obesity]. MMW Fortschritte der Medizin, 2003, Oct-16, Volume: 145, Issue:42 Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Body Mass Index; Clinical Trials as Topic; Cyclobutanes; Exercise; Humans; Lactones; Life Style; Middle Aged; Nutritional Physiological Phenomena; Obesity; Orlistat; Placebos; Psychotherapy; Risk Factors; Weight Loss	2003
[Effectiveness of therapeutic interventions in obesity]. Praxis, 2003, Nov-19, Volume: 92, Issue:47 Topics: Behavior Therapy; Combined Modality Therapy; Cross-Sectional Studies; Cyclobutanes; Diet, Reducing; Exercise; Gastroplasty; Humans; Incidence; Lactones; Lipids; Obesity; Orlistat; Switzerland; Treatment Outcome	2003
Obesity and pharmacologic therapy. Endocrinology and metabolism clinics of North America, 2003, Volume: 32, Issue:4 Topics: Anti-Obesity Agents; Cyclobutanes; Humans; Lactones; Obesity; Orlistat; Weight Loss	2003
What role for weight-loss medication? Weighing the pros and cons for obese patients. Postgraduate medicine, 2004, Volume: 115, Issue:1 Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Humans; Lactones; Life Style; Obesity; Orlistat; Patient Compliance; Treatment Outcome; Weight Loss	2004
Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. Health technology assessment (Winchester, England), 2004, Volume: 8, Issue:21 Topics: Anti-Obesity Agents; Behavior Therapy; Caloric Restriction; Cost-Benefit Analysis; Cyclobutanes; Diet, Fat-Restricted; Humans; Hypoglycemic Agents; Lactones; Markov Chains; Metformin; Obesity; Orlistat; Physical Fitness; Randomized Controlled Trials as Topic; Risk Factors	2004
Efficacy of pharmacotherapy for weight loss in adults with type 2 diabetes mellitus: a meta-analysis. Archives of internal medicine, 2004, Jul-12, Volume: 164, Issue:13 Topics: Adult; Aged; Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Diabetes Mellitus, Type 2; Drug Therapy; Female; Fluoxetine; Humans; Lactones; Male; Meta-Analysis as Topic; Middle Aged; Orlistat; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Weight Loss	2004
Long-term pharmacotherapy for obesity and overweight. The Cochrane database of systematic reviews, 2004, Issue:3 Topics: Anti-Obesity Agents; Appetite Depressants; Body Weight; Cyclobutanes; Humans; Lactones; Obesity; Orlistat; Randomized Controlled Trials as Topic; Weight Loss	2004
[Pharmacotherapy of obesity]. Wiener medizinische Wochenschrift (1946), 2004, Volume: 154, Issue:13-14 Topics: Appetite Depressants; Body Weight; Clinical Trials as Topic; Cyclobutanes; Diabetes Mellitus; Humans; Lactones; Obesity; Orlistat; Satiety Response; Treatment Outcome	2004
Clinical pharmacotherapy for obesity: current drugs and those in advanced development. Current drug targets, 2004, Volume: 5, Issue:7 Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Energy Metabolism; Feeding Behavior; Fructose; Humans; Lactones; Obesity; Orlistat; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Topiramate	2004
Pharmacological and surgical treatment of obesity. Evidence report/technology assessment (Summary), 2004, Issue:103 Topics: Adult; Appetite Depressants; Bupropion; Cyclobutanes; Diethylpropion; Fluoxetine; Fructose; Gastric Bypass; Gastroplasty; Humans; Lactones; Lipase; Obesity; Orlistat; Phentermine; Topiramate	2004
A perspective on the current strategies for the treatment of obesity. Current drug targets. CNS and neurological disorders, 2004, Volume: 3, Issue:5 Topics: Anti-Obesity Agents; Bariatrics; Chromium; Citrates; Cyclobutanes; Energy Intake; Ephedrine; Exercise Therapy; Garcinia cambogia; Herbal Medicine; Humans; Lactones; Linoleic Acids, Conjugated; Obesity; Orlistat; Phytotherapy; Pyruvic Acid	2004
Obesity. Clinical evidence, 2003, Issue:10 Topics: Adult; Appetite Depressants; Cyclobutanes; Diethylpropion; Fluoxetine; Humans; Lactones; Mazindol; Obesity; Orlistat; Phentermine; Phenylpropanolamine	2003
Modern, new pharmacotherapy for obesity. A gastrointestinal approach. Best practice & research. Clinical gastroenterology, 2004, Volume: 18, Issue:6 Topics: Amylases; Androgens; Anti-Obesity Agents; Citrates; Cyclobutanes; Dietary Fats; Fat Substitutes; Fatty Acids; Glucagon; Glucagon-Like Peptide 1; Glucosidases; Human Growth Hormone; Humans; Intestinal Absorption; Lactones; Lipase; Obesity; Orlistat; Peptide Fragments; Protein Precursors; Sucrose	2004
Medical management of obesity in women: office-based approaches to weight management. Clinical obstetrics and gynecology, 2004, Volume: 47, Issue:4 Topics: Appetite Depressants; Body Mass Index; Cyclobutanes; Exercise; Female; Humans; Lactones; Obesity; Orlistat; Women's Health	2004
Obesity. Clinical evidence, 2004, Issue:11 Topics: Adult; Appetite Depressants; Cyclobutanes; Diethylpropion; Fluoxetine; Humans; Lactones; Mazindol; Obesity; Orlistat; Phentermine; Phenylpropanolamine; Selective Serotonin Reuptake Inhibitors	2004
Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus. The Cochrane database of systematic reviews, 2005, Jan-25, Issue:1 Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Diabetes Mellitus, Type 2; Fluoxetine; Humans; Lactones; Obesity; Orlistat; Randomized Controlled Trials as Topic; Weight Loss	2005
Long-term pharmacotherapy for obesity. Obesity research, 2004, Volume: 12 Suppl Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Humans; Lactones; Obesity; Orlistat; Randomized Controlled Trials as Topic; Weight Loss	2004
Pharmacological treatments for obesity. Professional nurse (London, England), 2005, Volume: 20, Issue:8 Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Humans; Lactones; Leptin; Obesity; Orlistat	2005
Clinical evidence for drug treatments in obesity-associated hypertensive patients--a discussion paper. Methods and findings in experimental and clinical pharmacology, 2005, Volume: 27, Issue:2 Topics: Anti-Obesity Agents; Antihypertensive Agents; Appetite Depressants; Cyclobutanes; Humans; Hypertension; Insulin; Lactones; Lipids; Obesity; Orlistat	2005
Obesity and cardiovascular physiology: impact of some pharmacological agents. Current vascular pharmacology, 2005, Volume: 3, Issue:2 Topics: Animals; Anti-Obesity Agents; Appetite Depressants; Cardiovascular Diseases; Cardiovascular Physiological Phenomena; Clinical Trials as Topic; Cyclobutanes; Humans; Lactones; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant; Risk Factors	2005
Managing type 2 diabetes mellitus in patients with obesity. Treatments in endocrinology, 2004, Volume: 3, Issue:4 Topics: Anti-Obesity Agents; Appetite Depressants; Blood Glucose; Cyclobutanes; Diabetes Mellitus, Type 2; Diet, Reducing; Energy Intake; Gastric Bypass; Humans; Hypoglycemic Agents; Lactones; Obesity; Orlistat; Weight Loss	2004
Obesity. Clinical evidence, 2005, Issue:13 Topics: Adult; Appetite Depressants; Cyclobutanes; Diethylpropion; Fluoxetine; Gastric Bypass; Gastroplasty; Humans; Lactones; Mazindol; Obesity; Orlistat; Phentermine	2005
Childhood obesity. Treatment options. Best practice & research. Clinical endocrinology & metabolism, 2005, Volume: 19, Issue:3 Topics: Adolescent; Anti-Obesity Agents; Behavior Therapy; Child; Child Behavior; Cyclobutanes; Diet, Reducing; Dietary Fats; Humans; Lactones; Motor Activity; Obesity; Orlistat; Parents	2005
Pharmacologic agents for the treatment of obesity. Clinics in geriatric medicine, 2005, Volume: 21, Issue:4 Topics: Aged; Amphetamines; Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Humans; Lactones; Obesity; Orlistat	2005
Pharmacotherapy for obesity. Appetite, 2006, Volume: 46, Issue:1 Topics: Anti-Obesity Agents; Appetite Depressants; Cost of Illness; Cyclobutanes; Feeding Behavior; Humans; Lactones; Obesity; Orlistat; Treatment Outcome; Weight Loss	2006
New drug policy in childhood obesity. International journal of obesity (2005), 2005, Volume: 29 Suppl 2 Topics: Adolescent; Anti-Obesity Agents; Appetite Depressants; Child; Cyclobutanes; Drugs, Investigational; Enzyme Inhibitors; Humans; Lactones; Lipase; Obesity; Orlistat	2005
[Drug treatment of obesity]. Ugeskrift for laeger, 2006, Jan-09, Volume: 168, Issue:2 Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Diethylpropion; Enzyme Inhibitors; Humans; Lactones; Obesity; Orlistat; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Time Factors; Weight Loss	2006
Pharmacologic treatment of obesity. Advances in psychosomatic medicine, 2006, Volume: 27 Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Fructose; Humans; Isoxazoles; Lactones; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant; Selective Serotonin Reuptake Inhibitors; Topiramate; Zonisamide	2006
Pharmacotherapy to reduce visceral fat. Clinical cornerstone, 2005, Volume: 7, Issue:2-3 Topics: Anti-Obesity Agents; Coronary Disease; Cyclobutanes; Exercise; Feeding Behavior; Humans; Intra-Abdominal Fat; Lactones; Metabolic Syndrome; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant	2005
Weight loss as a treatment for nonalcoholic fatty liver disease. Journal of clinical gastroenterology, 2006, Volume: 40 Suppl 1 Topics: Anti-Obesity Agents; Appetite Depressants; Bariatric Surgery; Chronic Disease; Cyclobutanes; Diet, Reducing; Disease Progression; Fatty Liver; Humans; Lactones; Life Style; Orlistat; Weight Loss	2006
[Pharmacotherapy in the treatment of obesity]. MMW Fortschritte der Medizin, 2006, Mar-02, Volume: 148, Issue:9 Topics: Anti-Obesity Agents; Appetite Depressants; Cannabinoid Receptor Antagonists; Clinical Trials as Topic; Cyclobutanes; Enzyme Inhibitors; Exercise; Humans; Lactones; Lipase; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant; Time Factors; Weight Loss	2006
The obesity epidemic and its cardiovascular consequences. Current opinion in cardiology, 2006, Volume: 21, Issue:4 Topics: Appetite Depressants; Body Fat Distribution; Body Mass Index; Cardiovascular Diseases; Cyclobutanes; Humans; Inflammation; Insulin Resistance; Intra-Abdominal Fat; Lactones; Life Style; Lipid Metabolism; Metabolic Syndrome; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant; Thiazolidinediones; Waist-Hip Ratio	2006
Pharmacological treatment of obesity. Arquivos brasileiros de endocrinologia e metabologia, 2006, Volume: 50, Issue:2 Topics: Amphetamines; Anti-Obesity Agents; Appetite Depressants; Clinical Trials as Topic; Cyclobutanes; Energy Metabolism; Homeostasis; Humans; Lactones; Mazindol; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant; Weight Loss	2006
Weight loss medications--where do they fit in? Australian family physician, 2006, Volume: 35, Issue:8 Topics: Anti-Obesity Agents; Chronic Disease; Cyclobutanes; Diethylpropion; Humans; Lactones; Obesity; Orlistat; Phentermine; Weight Loss	2006
Emerging pharmacotherapy for treating obesity and associated cardiometabolic risk. Asia Pacific journal of clinical nutrition, 2006, Volume: 15 Suppl Topics: Anti-Obesity Agents; Cardiovascular Diseases; Cyclobutanes; Humans; Lactones; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant; Risk Factors; Safety; Treatment Outcome	2006
Use of lifestyle changes treatment plans and drug therapy in controlling cardiovascular and metabolic risk factors. Obesity (Silver Spring, Md.), 2006, Volume: 14 Suppl 3 Topics: Caloric Restriction; Cardiovascular Diseases; Cyclobutanes; Diabetes Mellitus; Diet; Diet, Fat-Restricted; Diet, Mediterranean; Exercise; Feeding Behavior; Food, Formulated; Humans; Lactones; Metabolic Syndrome; Obesity; Orlistat; Phentermine; Prediabetic State; Risk Reduction Behavior; Weight Loss	2006
Current and novel approaches to the drug therapy of obesity. European journal of clinical pharmacology, 2006, Volume: 62, Issue:10 Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Humans; Lactones; Models, Biological; Obesity; Orlistat; Weight Loss	2006
Pharmacologic treatment for obesity. Options for today...and tomorrow. Advance for nurse practitioners, 2006, Volume: 14, Issue:8 Topics: Anti-Obesity Agents; Clinical Trials as Topic; Cyclobutanes; Drug Therapy, Combination; Humans; Lactones; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant; Weight Loss	2006
The obesity epidemic: current and future pharmacological treatments. Annual review of pharmacology and toxicology, 2007, Volume: 47 Topics: Anti-Obesity Agents; Cyclobutanes; Disease Outbreaks; Drug Design; Drugs, Investigational; Humans; Lactones; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant	2007
Medical strategies for weight loss in the overweight and obese patient. Minerva gastroenterologica e dietologica, 2006, Volume: 52, Issue:4 Topics: Anti-Obesity Agents; Appetite Depressants; Behavior Therapy; Body Mass Index; Cyclobutanes; Exercise; Follow-Up Studies; Humans; Lactones; Life Style; Obesity; Orlistat; Overweight; Patient Compliance; Prospective Studies; Quality of Life; Randomized Controlled Trials as Topic; Risk Factors; Time Factors; Weight Loss	2006
Sibutramine for obesity in adolescents. Expert opinion on pharmacotherapy, 2006, Volume: 7, Issue:17 Topics: Adolescent; Appetite Depressants; Body Mass Index; Clinical Trials as Topic; Cyclobutanes; Female; Humans; Lactones; Male; Mexico; Obesity; Orlistat; United States	2006
Pharmacotherapy of obesity. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2006, Volume: 114, Issue:9 Topics: Anti-Obesity Agents; Clinical Trials as Topic; Cyclobutanes; Drug Design; Energy Metabolism; Homeostasis; Humans; Lactones; Life Style; Models, Biological; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant; Technology, Pharmaceutical	2006
Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet (London, England), 2007, Jan-06, Volume: 369, Issue:9555 Topics: Anti-Obesity Agents; Blood Pressure; Cholesterol, HDL; Cyclobutanes; Half-Life; Humans; Lactones; Obesity; Orlistat; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Weight Loss	2007
[Pharmacotherapy of obesity]. Medizinische Monatsschrift fur Pharmazeuten, 2006, Volume: 29, Issue:12 Topics: Anti-Obesity Agents; Anticonvulsants; Cyclobutanes; Fructose; Humans; Lactones; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant; Topiramate	2006
Currently available drugs for the treatment of obesity: Sibutramine and orlistat. Mini reviews in medicinal chemistry, 2007, Volume: 7, Issue:1 Topics: Anti-Obesity Agents; Body Weight; Cyclobutanes; Energy Metabolism; Exercise; Humans; Lactones; Obesity; Orlistat	2007
Weight management for type 2 diabetes mellitus: global cardiovascular risk reduction. The American journal of cardiology, 2007, Feb-19, Volume: 99, Issue:4A Topics: Anti-Obesity Agents; Cannabinoid Receptor Antagonists; Cardiovascular Diseases; Cyclobutanes; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Lactones; Life Style; Obesity; Orlistat	2007
Therapeutic options for modifying cardiometabolic risk factors. The American journal of medicine, 2007, Volume: 120, Issue:3 Suppl 1 Topics: Anti-Obesity Agents; Appetite Depressants; Cardiovascular Diseases; Cyclobutanes; Humans; Hypoglycemic Agents; Lactones; Metabolic Syndrome; Obesity; Orlistat; Practice Guidelines as Topic; Receptor, Cannabinoid, CB1; Weight Loss	2007
[Childhood obesity. Recommendations of the Nutrition Committee of the Spanish Association of Pediatrics. Part II. Diagnosis. Comorbidities. Treatment]. Anales de pediatria (Barcelona, Spain : 2003), 2007, Volume: 66, Issue:3 Topics: Anti-Obesity Agents; Appetite Depressants; Cardiovascular Diseases; Child; Combined Modality Therapy; Cyclobutanes; Fatty Liver; Gastric Bypass; Humans; Hypercholesterolemia; Hypertension; Insulin Resistance; Lactones; Metabolic Syndrome; Obesity; Orlistat; Risk Factors	2007
[New therapeutic aspects for the control of risk factors in obesity]. Medicina clinica, 2007, Apr-07, Volume: 128, Issue:13 Topics: Anti-Obesity Agents; Cyclobutanes; Humans; Lactones; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant	2007
Drug treatment of the overweight patient. Gastroenterology, 2007, Volume: 132, Issue:6 Topics: Animals; Anti-Obesity Agents; Clinical Trials, Phase II as Topic; Cyclobutanes; Humans; Lactones; Obesity; Orlistat; Overweight; Piperidines; Pyrazoles; Rimonabant; Treatment Outcome	2007
Pharmacotherapeutic options for overweight adolescents. The Annals of pharmacotherapy, 2007, Volume: 41, Issue:9 Topics: Adolescent; Anti-Obesity Agents; Clinical Trials as Topic; Cyclobutanes; Humans; Hypoglycemic Agents; Lactones; Metformin; Obesity; Orlistat; Overweight	2007
Drugs in the treatment of obesity: sibutramine, orlistat and rimonabant. Public health nutrition, 2007, Volume: 10, Issue:10A Topics: Anti-Obesity Agents; Cyclobutanes; Humans; Lactones; Life Style; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant; Safety; Treatment Outcome; Weight Loss	2007
Weight-loss outcomes: a systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up. Journal of the American Dietetic Association, 2007, Volume: 107, Issue:10 Topics: Adult; Anti-Obesity Agents; Combined Modality Therapy; Cyclobutanes; Diet, Reducing; Exercise; Female; Follow-Up Studies; Food, Formulated; Humans; Lactones; Longitudinal Studies; Male; Obesity; Orlistat; Treatment Outcome; Weight Loss	2007
Orlistat and sibutramine beyond weight loss. Nutrition, metabolism, and cardiovascular diseases : NMCD, 2008, Volume: 18, Issue:5 Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Cardiovascular Diseases; Cyclobutanes; Humans; Hyperlipidemias; Hypolipidemic Agents; Lactones; Lipids; Middle Aged; Obesity; Orlistat; Treatment Outcome; Weight Loss	2008
[Obesity: a review of currently used antiobesity drugs and new compounds in clinical development]. Postepy higieny i medycyny doswiadczalnej (Online), 2007, Oct-19, Volume: 61 Topics: Anti-Obesity Agents; Clinical Trials as Topic; Cyclobutanes; Humans; Lactones; Neurotransmitter Agents; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant; Treatment Outcome	2007
[Obesity in adults]. Praxis, 2007, Oct-17, Volume: 96, Issue:42 Topics: Adult; Aged; Anti-Obesity Agents; Appetite Depressants; Bariatric Surgery; Body Mass Index; Cyclobutanes; Diagnosis, Differential; Enzyme Inhibitors; Humans; Lactones; Male; Middle Aged; Obesity; Obesity, Morbid; Orlistat; Overweight; Piperidines; Prognosis; Pyrazoles; Rimonabant; Time Factors; Weight Loss	2007
Strategies to reduce vascular risk associated with obesity. Current vascular pharmacology, 2007, Volume: 5, Issue:4 Topics: Adiponectin; Anti-Obesity Agents; Cardiovascular Diseases; Cyclobutanes; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypertension; Lactones; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant; Risk Factors	2007
[Pharmacotherapy of obesity]. Der Internist, 2008, Volume: 49, Issue:1 Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Humans; Lactones; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant; Treatment Outcome	2008
Head-to-head studies evaluating efficacy of pharmaco-therapy for obesity: a systematic review and meta-analysis. Obesity reviews : an official journal of the International Association for the Study of Obesity, 2008, Volume: 9, Issue:5 Topics: Anti-Obesity Agents; Cyclobutanes; Female; Humans; Lactones; Male; Obesity; Orlistat; Randomized Controlled Trials as Topic; Treatment Outcome; Weight Loss	2008
Obesity: a review of pathogenesis and management strategies. Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2008, Volume: 22, Issue:1 Topics: Anti-Obesity Agents; Bariatric Surgery; Behavior Therapy; Caloric Restriction; Cyclobutanes; Dietary Carbohydrates; Dietary Fats; Exercise; Humans; Lactones; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant; Weight Loss	2008
Emerging concepts in the medical and surgical treatment of obesity. Frontiers of hormone research, 2008, Volume: 36 Topics: Adipose Tissue; Amyloid; Anticonvulsants; Antidepressive Agents; Anxiety; Appetite Regulation; Bariatric Surgery; Body Mass Index; Bupropion; Cholecystokinin; Ciliary Neurotrophic Factor; Clinical Trials as Topic; Cyclobutanes; Depression; Diabetes Mellitus, Type 2; Female; Fluoxetine; Fructose; Ghrelin; Humans; Intra-Abdominal Fat; Islet Amyloid Polypeptide; Isoxazoles; Lactones; Leptin; Metabolic Syndrome; Metformin; Obesity; Obesity, Morbid; Orlistat; Oxyntomodulin; Peptide YY; Piperidines; Polycystic Ovary Syndrome; Pyrazoles; Rimonabant; Sertraline; Sleep Apnea, Obstructive; Surgical Procedures, Operative; Topiramate; Zonisamide	2008
Long-term effects of weight-reducing interventions in hypertensive patients: systematic review and meta-analysis. Archives of internal medicine, 2008, Mar-24, Volume: 168, Issue:6 Topics: Appetite Depressants; Blood Pressure; Cyclobutanes; Humans; Hypertension; Lactones; Obesity; Orlistat; Time Factors; Treatment Outcome; Weight Loss	2008
Pharmacotherapy for obesity. Current atherosclerosis reports, 2007, Volume: 9, Issue:6 Topics: Amyloid; Anti-Obesity Agents; Appetite Depressants; Body Weight; Chronic Disease; Comorbidity; Cyclobutanes; Exenatide; Gastrointestinal Hormones; Humans; Islet Amyloid Polypeptide; Lactones; Leptin; Metformin; Obesity; Orlistat; Peptides; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Venoms	2007
Pharmacotherapy for obesity in menopausal women. Menopause international, 2008, Volume: 14, Issue:2 Topics: Anti-Obesity Agents; Bariatric Surgery; Cyclobutanes; Diabetes Mellitus, Type 2; Exenatide; Female; Humans; Hypoglycemic Agents; Lactones; Menopause; Metformin; Obesity; Orlistat; Peptides; Piperidines; Pyrazoles; Rimonabant; Risk Factors; Venoms	2008
Cost-effectiveness of pharmacological anti-obesity treatments: a systematic review. International journal of obesity (2005), 2008, Volume: 32, Issue:12 Topics: Anti-Obesity Agents; Appetite Depressants; Body Mass Index; Cost-Benefit Analysis; Cyclobutanes; Europe; Humans; Lactones; Obesity; Orlistat; Piperidines; Pyrazoles; Quality-Adjusted Life Years; Rimonabant; Treatment Outcome; United States	2008
Pharmacotherapy for eating disorders and obesity. Child and adolescent psychiatric clinics of North America, 2009, Volume: 18, Issue:1 Topics: Adolescent; Anorexia Nervosa; Anticonvulsants; Antipsychotic Agents; Appetite Depressants; Behavior Therapy; Bulimia Nervosa; Child; Combined Modality Therapy; Cyclobutanes; Feeding and Eating Disorders; Humans; Lactones; Obesity; Orlistat; Psychotropic Drugs; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors	2009
Current pharmacotherapeutic concepts for the treatment of obesity in adults. Therapeutic advances in cardiovascular disease, 2009, Volume: 3, Issue:1 Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Combined Modality Therapy; Cyclobutanes; Enzyme Inhibitors; Humans; Lactones; Lipase; Obesity; Orlistat; Piperidines; Prevalence; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Reduction Behavior; Treatment Outcome; Weight Loss	2009
Recent advances in obesity pharmacotherapy. Current clinical pharmacology, 2009, Volume: 4, Issue:1 Topics: Animals; Anti-Obesity Agents; Cardiovascular Diseases; Cyclobutanes; Humans; Lactones; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant	2009
Effect of antiobesity medications in patients with type 2 diabetes mellitus. Diabetes, obesity & metabolism, 2009, Volume: 11, Issue:7 Topics: Adolescent; Adult; Aged; Anti-Obesity Agents; Appetite Depressants; Body Weight; Cyclobutanes; Diabetes Mellitus, Type 2; Female; Humans; Lactones; Male; Middle Aged; Obesity; Orlistat; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Receptor, Cannabinoid, CB1; Rimonabant; Treatment Outcome; Weight Loss; Young Adult	2009
Effectiveness of weight management programs in children and adolescents. Evidence report/technology assessment, 2008, Issue:170 Topics: Adolescent; Anti-Obesity Agents; Appetite Depressants; Bariatric Surgery; Behavior Therapy; Child; Child, Preschool; Cyclobutanes; Humans; Lactones; Obesity; Orlistat; Weight Loss	2008
Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis. Obesity reviews : an official journal of the International Association for the Study of Obesity, 2009, Volume: 10, Issue:5 Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Humans; Lactones; Medication Adherence; Odds Ratio; Orlistat; Overweight; Patient Dropouts; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant	2009
The first decade of sibutramine and orlistat: a reappraisal of their expanding roles in the treatment of obesity and associated conditions. Arquivos brasileiros de endocrinologia e metabologia, 2009, Volume: 53, Issue:2 Topics: Adolescent; Adult; Anti-Obesity Agents; Appetite Depressants; Clinical Trials as Topic; Cyclobutanes; Evidence-Based Medicine; Humans; Lactones; Obesity; Orlistat; Practice Guidelines as Topic; Weight Loss	2009
Efficacy of weight loss drugs on obesity and cardiovascular risk factors in obese adolescents: a meta-analysis of randomized controlled trials. Obesity reviews : an official journal of the International Association for the Study of Obesity, 2010, Volume: 11, Issue:2 Topics: Adolescent; Anti-Obesity Agents; Cardiovascular Diseases; Cyclobutanes; Humans; Lactones; Lipids; Obesity; Orlistat; Randomized Controlled Trials as Topic; Risk Factors; Weight Loss	2010
Long-term effects of weight-reducing drugs in hypertensive patients. The Cochrane database of systematic reviews, 2009, Jul-08, Issue:3 Topics: Adult; Anti-Obesity Agents; Blood Pressure; Cyclobutanes; Female; Humans; Hypertension; Lactones; Male; Middle Aged; Orlistat; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Time; Weight Loss	2009
What are the risks and the benefits of current and emerging weight-loss medications? Current diabetes reports, 2009, Volume: 9, Issue:5 Topics: Anti-Obesity Agents; Cyclobutanes; Humans; Lactones; Obesity; Orlistat; Weight Loss	2009
Efficacy and safety of anti-obesity drugs in children and adolescents: systematic review and meta-analysis. Obesity reviews : an official journal of the International Association for the Study of Obesity, 2010, Volume: 11, Issue:8 Topics: Adolescent; Anti-Obesity Agents; Appetite Depressants; Body Mass Index; Child; Cognitive Behavioral Therapy; Combined Modality Therapy; Consumer Product Safety; Cyclobutanes; Female; Humans; Lactones; Male; Obesity; Orlistat; Randomized Controlled Trials as Topic; Treatment Outcome; Waist Circumference; Weight Loss	2010
Long-term changes in blood pressure following orlistat and sibutramine treatment: a meta-analysis. Obesity reviews : an official journal of the International Association for the Study of Obesity, 2010, Volume: 11, Issue:11 Topics: Adult; Anti-Obesity Agents; Blood Pressure; Cyclobutanes; Diabetes Mellitus, Type 2; Humans; Lactones; Middle Aged; Obesity; Orlistat; Randomized Controlled Trials as Topic; Weight Loss	2010
Effectiveness of weight management interventions in children: a targeted systematic review for the USPSTF. Pediatrics, 2010, Volume: 125, Issue:2 Topics: Adolescent; Appetite Depressants; Behavior Therapy; Child; Child, Preschool; Counseling; Cyclobutanes; Female; Humans; Lactones; Obesity; Orlistat; Overweight; Primary Health Care; Treatment Outcome	2010
Pharmacologic therapies for obesity. Gastroenterology clinics of North America, 2010, Volume: 39, Issue:1 Topics: Anti-Obesity Agents; Appetite Depressants; Bariatric Surgery; Benzazepines; Bupropion; Cyclobutanes; Ephedrine; Fenfluramine; Humans; Lactones; Naltrexone; Obesity; Orlistat; Phentermine; Weight Gain; Weight Loss	2010
Office-based strategies for the management of obesity. American family physician, 2010, Jun-15, Volume: 81, Issue:12 Topics: Adult; Anti-Obesity Agents; Bariatric Surgery; Body Mass Index; Child; Counseling; Cyclobutanes; Diet, Reducing; Female; Humans; Lactones; Male; Obesity; Orlistat; Risk Factors	2010
A systematic review and mixed treatment comparison of pharmacological interventions for the treatment of obesity. Obesity reviews : an official journal of the International Association for the Study of Obesity, 2012, Volume: 13, Issue:6 Topics: Anti-Obesity Agents; Body Mass Index; Cyclobutanes; Humans; Lactones; Life Style; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant; Treatment Outcome; Weight Loss	2012
What is the clinical effectiveness and cost-effectiveness of using drugs in treating obese patients in primary care? A systematic review. Health technology assessment (Winchester, England), 2012, Volume: 16, Issue:5 Topics: Anti-Obesity Agents; Cost-Benefit Analysis; Cyclobutanes; Drug Costs; Exercise; Female; Humans; Lactones; Male; Middle Aged; Obesity; Orlistat; Piperidines; Primary Health Care; Pyrazoles; Rimonabant; Risk Reduction Behavior; Treatment Outcome	2012
[The pharmacological treatment of obesity: past, present and future]. Orvosi hetilap, 2012, Mar-11, Volume: 153, Issue:10 Topics: Amides; Anti-Obesity Agents; Anticonvulsants; Antidepressive Agents; Basal Metabolism; Benzazepines; Benzoxazines; Body Mass Index; Bridged Bicyclo Compounds, Heterocyclic; Ciliary Neurotrophic Factor; Clinical Trials as Topic; Combined Modality Therapy; Cyclobutanes; Dexfenfluramine; Fatty Acids; Female; Fenfluramine; Glucagon-Like Peptide 1; Human Growth Hormone; Humans; Intestinal Absorption; Lactones; Leptin; Life Style; Liraglutide; Male; Norepinephrine; Obesity; Obesity, Morbid; Orlistat; Piperidines; Pyrazoles; Pyridines; Receptor, Melanocortin, Type 4; Rimonabant; Satiation; Serotonin; Sodium-Glucose Transport Proteins; Sucrose; Thyroid Hormones	2012
The clinical treatment of childhood obesity. Indian journal of pediatrics, 2013, Volume: 80 Suppl 1 Topics: Adolescent; Bariatric Surgery; Behavior Therapy; Child; Child, Preschool; Combined Modality Therapy; Cooperative Behavior; Cyclobutanes; Energy Intake; Evidence-Based Medicine; Humans; Infant; Interdisciplinary Communication; Lactones; Life Style; Metformin; Motor Activity; Orlistat; Overweight; Pediatric Obesity; Pediatrics; Physician's Role; Practice Guidelines as Topic; Risk Factors; Young Adult	2013
Obesity and diabetes. Handbook of experimental pharmacology, 2012, Issue:214 Topics: Animals; Cyclobutanes; Diabetes Mellitus; Female; Humans; Incretins; Insulin; Lactones; Male; Metformin; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant; Sex Characteristics; Sulfonylurea Compounds	2012
Long-term effects of weight-reducing drugs in hypertensive patients. The Cochrane database of systematic reviews, 2013, Mar-28, Issue:3 Topics: Adult; Anti-Obesity Agents; Blood Pressure; Cyclobutanes; Diet, Reducing; Female; Humans; Hypertension; Lactones; Male; Middle Aged; Orlistat; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Safety-Based Drug Withdrawals; Time; Weight Loss	2013
Food ingredients as anti-obesity agents: a review. Critical reviews in food science and nutrition, 2013, Volume: 53, Issue:9 Topics: Anti-Obesity Agents; Calcium, Dietary; Cyclobutanes; Diet; Dietary Fiber; Energy Metabolism; Exercise; Fatty Acids, Unsaturated; Food Analysis; Food Handling; Glycine max; Humans; Lactones; Life Style; Obesity; Orlistat; Phytosterols; Polyphenols; United States; United States Food and Drug Administration; Weight Loss	2013
Obesity drug therapy. Minerva endocrinologica, 2013, Volume: 38, Issue:3 Topics: Anti-Obesity Agents; Appetite; Combined Modality Therapy; Comorbidity; Cost-Benefit Analysis; Cyclobutanes; Diabetes Mellitus, Type 2; Diet, Diabetic; Drug Combinations; Exercise Therapy; Fructose; Gastrointestinal Hormones; Humans; Incretins; Insulin; Insulin Secretion; Intestines; Lactones; Leptin; Life Style; Models, Biological; Neuropeptides; Obesity; Orlistat; Phentermine; Phytotherapy; Piperidines; Plant Preparations; Pyrazoles; Rimonabant; Topiramate	2013
Long-term effects of weight-reducing drugs in people with hypertension. The Cochrane database of systematic reviews, 2016, Mar-02, Volume: 3 Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Blood Pressure; Cyclobutanes; Diet, Reducing; Female; Fructose; Humans; Hypertension; Lactones; Male; Middle Aged; Orlistat; Phentermine; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Safety-Based Drug Withdrawals; Time; Topiramate; Weight Loss	2016
Drug interventions for the treatment of obesity in children and adolescents. The Cochrane database of systematic reviews, 2016, Nov-29, Volume: 11 Topics: Adolescent; Anti-Obesity Agents; Body Mass Index; Child; Cyclobutanes; Fluoxetine; Humans; Lactones; Metformin; Orlistat; Pediatric Obesity; Randomized Controlled Trials as Topic	2016
Treatment of Pediatric Obesity: An Umbrella Systematic Review. The Journal of clinical endocrinology and metabolism, 2017, 03-01, Volume: 102, Issue:3 Topics: Adolescent; Anti-Obesity Agents; Appetite Depressants; Bariatric Surgery; Behavior Therapy; Blood Glucose; Blood Pressure; Body Mass Index; Child; Cholesterol, HDL; Cyclobutanes; Diet Therapy; Diet, Carbohydrate-Restricted; Diet, Fat-Restricted; Exercise; Exercise Therapy; Gastrectomy; Gastric Bypass; Humans; Hypoglycemic Agents; Lactones; Metformin; Orlistat; Patient Education as Topic; Pediatric Obesity; Treatment Outcome; Triglycerides; Waist Circumference	2017

Trials

18 trial(s) available for sibutramine and orlistat

Article	Year
Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial. Obesity research, 2000, Volume: 8, Issue:6 Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Body Mass Index; Body Weight; Combined Modality Therapy; Cyclobutanes; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Lactones; Life Style; Middle Aged; Obesity; Orlistat; Pilot Projects; Time Factors	2000
Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity. Diabetes, obesity & metabolism, 2002, Volume: 4, Issue:1 Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Blood Glucose; Body Mass Index; Body Weight; Cyclobutanes; Diabetes Mellitus; Female; Humans; Hypoglycemic Agents; Lactones; Metformin; Obesity; Orlistat; Postprandial Period; Safety; Treatment Outcome; Weight Loss	2002
The cerebrospinal fluid/serum leptin ratio during pharmacological therapy for obesity. The Journal of clinical endocrinology and metabolism, 2002, Volume: 87, Issue:4 Topics: Adolescent; Adult; Amphetamines; Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Humans; Lactones; Leptin; Middle Aged; Obesity; Orlistat; Weight Loss	2002
The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-alcoholic steatohepatitis. Romanian journal of gastroenterology, 2003, Volume: 12, Issue:3 Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Enzyme Inhibitors; Fatty Liver; Female; Humans; Insulin Resistance; Lactones; Lipase; Liver; Male; Obesity; Orlistat; Ultrasonography; Weight Loss	2003
Orlistat, sibutramine, or combination therapy: which performs better on waist circumference in relation with body mass index in obese patients? The Tohoku journal of experimental medicine, 2004, Volume: 202, Issue:3 Topics: Adult; Anthropometry; Anti-Obesity Agents; Body Mass Index; Body Weight; Combined Modality Therapy; Cyclobutanes; Diet, Reducing; Drug Therapy, Combination; Female; Humans; Lactones; Male; Middle Aged; Obesity; Orlistat; Statistics as Topic	2004
Comparison of efficacy of sibutramine or orlistat versus their combination in obese women. Endocrine research, 2004, Volume: 30, Issue:2 Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Diet, Reducing; Female; Humans; Lactones; Middle Aged; Obesity; Orlistat; Treatment Outcome; Weight Loss	2004
Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients. Diabetes, nutrition & metabolism, 2004, Volume: 17, Issue:4 Topics: Anthropometry; Anti-Obesity Agents; Blood Pressure; Cyclobutanes; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Heart Rate; Humans; Lactones; Male; Middle Aged; Obesity; Orlistat; Safety; Treatment Outcome; Weight Loss	2004
Efficacy of sibutramine, orlistat and combination therapy on short-term weight management in obese patients. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2004, Volume: 58, Issue:10 Topics: Adult; Body Mass Index; Cyclobutanes; Diet, Reducing; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Lactones; Male; Middle Aged; Obesity; Orlistat; Prospective Studies; Time Factors; Weight Loss	2004
Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients. Diabetes, obesity & metabolism, 2005, Volume: 7, Issue:1 Topics: Analysis of Variance; Appetite Depressants; Blood Pressure; Cyclobutanes; Double-Blind Method; Female; Heart Rate; Humans; Hypertension; Lactones; Male; Middle Aged; Obesity; Orlistat	2005
Comparison of orlistat and sibutramine in an obesity management program: efficacy, compliance, and weight regain after noncompliance. Eating and weight disorders : EWD, 2006, Volume: 11, Issue:4 Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Combined Modality Therapy; Cyclobutanes; Diet, Reducing; Exercise Therapy; Female; Humans; Lactones; Male; Middle Aged; Obesity; Orlistat; Patient Compliance; Prospective Studies; Weight Gain; Weight Loss	2006
Effects of sibutramine and orlistat on mood in obese and overweight subjects: a randomised study. Nutrition, metabolism, and cardiovascular diseases : NMCD, 2008, Volume: 18, Issue:3 Topics: Adult; Affect; Analysis of Variance; Anti-Obesity Agents; Appetite Depressants; Body Mass Index; Cyclobutanes; Diet, Reducing; Female; Humans; Lactones; Middle Aged; Obesity; Orlistat; Overweight; Prospective Studies; Psychometrics; Treatment Outcome; Weight Loss	2008
NPY5R antagonism does not augment the weight loss efficacy of orlistat or sibutramine. Obesity (Silver Spring, Md.), 2007, Volume: 15, Issue:8 Topics: Adolescent; Adult; Aged; Anti-Obesity Agents; Cyclobutanes; Cyclohexanes; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Female; Humans; Lactones; Male; Middle Aged; Obesity; Orlistat; Pyrazoles; Receptors, Neuropeptide Y; Spiro Compounds; Weight Loss	2007
Weight loss significantly reduces serum lipocalin-2 levels in overweight and obese women with polycystic ovary syndrome. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2012, Volume: 28, Issue:1 Topics: Acute-Phase Proteins; Adolescent; Adult; Anti-Obesity Agents; Caloric Restriction; Combined Modality Therapy; Cyclobutanes; Down-Regulation; Exercise Therapy; Female; Humans; Lactones; Lipocalin-2; Lipocalins; Metformin; Obesity; Orlistat; Overweight; Polycystic Ovary Syndrome; Proto-Oncogene Proteins; Weight Loss; Young Adult	2012
Effect of the G-protein β3 subunit 825T allele on the change of body adiposity in obese female. Diabetes, obesity & metabolism, 2013, Volume: 15, Issue:3 Topics: Adiposity; Adult; Alleles; Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Drug Synergism; Female; Genotype; GTP-Binding Proteins; Heterotrimeric GTP-Binding Proteins; Humans; Lactones; Middle Aged; Obesity; Orlistat; Polymorphism, Genetic; Weight Loss	2013
The effects of anti-obesity intervention with orlistat and sibutramine on microvascular endothelial function. Clinical hemorheology and microcirculation, 2015, Volume: 59, Issue:4 Topics: Adolescent; Adult; Aged; Anthropometry; Anti-Obesity Agents; Blood Pressure; Cholesterol; Cyclobutanes; Endothelium, Vascular; Female; Heart Rate; Humans; Lactones; Laser-Doppler Flowmetry; Male; Microvessels; Middle Aged; Obesity; Orlistat; Prospective Studies; Young Adult	2015
Effects of CYP3A5, CYP2C19, and CYP2B6 on the clinical efficacy and adverse outcomes of sibutramine therapy: a crucial role for the CYP2B66 allele. Clinica chimica acta; international journal of clinical chemistry, 2014, Jan-20, Volume: 428* Topics: Adolescent; Adult; Alleles; Cyclobutanes; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Double-Blind Method; Female; Genotype; Heart Rate; Humans; Lactones; Middle Aged; Orlistat; Polymorphism, Genetic; Prospective Studies; Pulse; Regression Analysis; Treatment Outcome; Weight Loss; Young Adult	2014
Influence of eating behaviors on short-term weight loss by orlistat and anorectic agent. Eating behaviors, 2014, Volume: 15, Issue:1 Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Double-Blind Method; Drug Therapy, Combination; Emotions; Feeding Behavior; Female; Humans; Lactones; Middle Aged; Obesity; Orlistat; Prospective Studies; Surveys and Questionnaires; Time Factors; Treatment Outcome; Weight Loss	2014
Metabolic and Inflammatory Changes with Orlistat and Sibutramine Treatment in Obese Malaysian Subjects. Journal of Nippon Medical School = Nippon Ika Daigaku zasshi, 2017, Volume: 84, Issue:3 Topics: Adiponectin; Adolescent; Adult; Aged; Asian People; Blood Glucose; Body Fat Distribution; Body Mass Index; C-Reactive Protein; Cardiovascular Diseases; Cyclobutanes; Fasting; Humans; Insulin; Insulin Resistance; Intra-Abdominal Fat; Lactones; Malaysia; Middle Aged; Obesity; Orlistat; Risk; Treatment Outcome; Waist Circumference; Young Adult	2017

Other Studies

62 other study(ies) available for sibutramine and orlistat

Article	Year
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
Anti-obesity drugs. The Medical journal of Australia, 1998, Apr-20, Volume: 168, Issue:8 Topics: Adrenergic Agonists; Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Humans; Lactones; Lipase; Obesity; Orlistat; Selective Serotonin Reuptake Inhibitors; Serotonin Receptor Agonists	1998
Orlistat for obesity. The Medical letter on drugs and therapeutics, 1999, Jun-18, Volume: 41, Issue:1055 Topics: Anti-Obesity Agents; Appetite Depressants; Clinical Trials as Topic; Cyclobutanes; Double-Blind Method; Drug Therapy, Combination; Enzyme Inhibitors; Fees, Pharmaceutical; Humans; Intestinal Absorption; Lactones; Lipase; Obesity; Orlistat; Phentermine	1999
New pharmacological directions for the treatment of overweight and obesity. Acta clinica Belgica, 1999, Volume: 54, Issue:3 Topics: Anti-Obesity Agents; Appetite Depressants; Body Mass Index; Body Weight; Cyclobutanes; Enzyme Inhibitors; Humans; Lactones; Obesity; Obesity, Morbid; Orlistat; Patient Selection; Weight Loss	1999
[How safe are the new obesity drugs? Indications and contraindications of orlistat and sibutramine]. MMW Fortschritte der Medizin, 1999, Dec-09, Volume: 141, Issue:49-50 Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Clinical Trials as Topic; Contraindications; Cyclobutanes; Drug Interactions; Humans; Lactones; Obesity; Orlistat; Treatment Outcome	1999
[No progress without the physician in therapy of obesity]. MMW Fortschritte der Medizin, 2000, Jan-27, Volume: 142, Issue:4 Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Humans; Lactones; Life Style; Obesity; Orlistat; Patient Education as Topic; Physician-Patient Relations	2000
Prevention and management of obesity: pharmacology . The Proceedings of the Nutrition Society, 2000, Volume: 59, Issue:3 Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Humans; Lactones; Obesity; Orlistat	2000
[Evolution and weight and body composition determination after therapy for pathological obesity for measuring compliance in (re)-education]. Bulletin de la Societe des sciences medicales du Grand-Duche de Luxembourg, 2000, Issue:1 Topics: Anti-Obesity Agents; Body Composition; Body Weight; Cyclobutanes; Diet, Reducing; Electric Impedance; Exercise; Female; Humans; Lactones; Male; Middle Aged; Nutritional Physiological Phenomena; Obesity; Orlistat; Patient Compliance; Patient Education as Topic; Retrospective Studies; Weight Loss	2000
[The role of pharmacotherapy for treatment of obesity in adults]. Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2000, Volume: 9, Issue:53 Topics: Adult; Animals; Anti-Obesity Agents; Chlorphentermine; Cyclobutanes; Dexfenfluramine; Dopamine Agonists; Ephedrine; Fluoxetine; Humans; Lactones; Mazindol; Obesity; Orlistat	2000
Toward optimal health: the experts discuss weight control drugs. Interview by Jodi Godfrey Meisler. Journal of women's health & gender-based medicine, 2001, Volume: 10, Issue:2 Topics: Anti-Obesity Agents; Appetite Depressants; Body Mass Index; Counseling; Cyclobutanes; Diet, Reducing; Drug Therapy, Combination; Exercise; Female; Humans; Lactones; Leptin; Life Style; Obesity; Orlistat; Patient Education as Topic; Patient Selection; Primary Health Care; United States; Weight Loss; Women's Health	2001
[Drugs for obesity. Why are obese patients diferent?]. Medicina clinica, 2001, Nov-03, Volume: 117, Issue:14 Topics: Adult; Anti-Obesity Agents; Child; Cyclobutanes; Female; Humans; Insurance, Pharmaceutical Services; Lactones; Male; Obesity; Orlistat; Spain	2001
Can drugs help you lose weight? Harvard heart letter : from Harvard Medical School, 2002, Volume: 12, Issue:7 Topics: Appetite Depressants; Body Weight; Cyclobutanes; Humans; Lactones; Orlistat; Weight Loss	2002
[Anti-obesity drugs: sibutramine and orlistat]. Medicina clinica, 2002, Mar-30, Volume: 118, Issue:11 Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Humans; Lactones; Obesity; Orlistat	2002
[New drugs for the treatment of obesity]. Duodecim; laaketieteellinen aikakauskirja, 1999, Volume: 115, Issue:20 Topics: Anti-Obesity Agents; Appetite Depressants; Clinical Trials as Topic; Cyclobutanes; Diet; Humans; Lactones; Obesity; Orlistat; Time Factors; Treatment Outcome; Weight Loss	1999
Obesity drug pipeline not so fat. Science (New York, N.Y.), 2003, Feb-07, Volume: 299, Issue:5608 Topics: Agouti-Related Protein; alpha-MSH; Animals; Anti-Obesity Agents; Appetite; Arcuate Nucleus of Hypothalamus; Ciliary Neurotrophic Factor; Clinical Trials as Topic; Cyclobutanes; Energy Intake; Ghrelin; Humans; Hunger; Intercellular Signaling Peptides and Proteins; Lactones; Leptin; Mice; Nerve Tissue Proteins; Neurons; Neuropeptide Y; Obesity; Orlistat; Peptide Fragments; Peptide Hormones; Peptide YY; Phentermine; Proteins; Receptors, Corticotropin; Receptors, Melanocortin; Weight Loss	2003
Experimental drugs take aim at obesity. JAMA, 2003, Apr-09, Volume: 289, Issue:14 Topics: Animals; Anti-Obesity Agents; Ciliary Neurotrophic Factor; Cyclobutanes; Drug Evaluation; Drugs, Investigational; Humans; Lactones; Obesity; Orlistat; Piperidines; Pyrazoles; Recombinant Proteins; Rimonabant; United States; United States Food and Drug Administration	2003
[Overweight patient has tried many times to lose weight. What helps against stubborn fat padding?]. MMW Fortschritte der Medizin, 2003, Mar-06, Volume: 145, Issue:10 Topics: Anti-Obesity Agents; Appetite Depressants; Contraindications; Cyclobutanes; Diet, Reducing; Exercise; Humans; Lactones; Obesity; Orlistat; Time Factors	2003
[A drug help in reducing? Risk profile decides whether and how]. MMW Fortschritte der Medizin, 2003, May-22, Volume: 145, Issue:21 Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Blood Glucose; Body Mass Index; Cyclobutanes; Diabetes Complications; Diabetes Mellitus; Humans; Hypertension; Lactones; Obesity; Orlistat; Risk Factors; Time Factors	2003
Management of the overweight patient with Type 2 diabetes. Diabetic medicine : a journal of the British Diabetic Association, 2003, Volume: 20 Suppl 4 Topics: Anti-Obesity Agents; Cyclobutanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Lactones; Metformin; Middle Aged; Obesity; Orlistat; Selective Serotonin Reuptake Inhibitors; Sulfonylurea Compounds	2003
The implementation of nutritional advice for people with diabetes. Diabetic medicine : a journal of the British Diabetic Association, 2003, Volume: 20, Issue:10 Topics: Adolescent; Adult; Aged; Anti-Obesity Agents; Asian People; Body Composition; Child; Cyclobutanes; Diabetes Mellitus; Diet; Dietary Services; Exercise; Feeding and Eating Disorders; Female; Glycemic Index; Humans; Insulin; Lactones; Male; Middle Aged; Nutritional Physiological Phenomena; Orlistat; Patient Education as Topic; Pregnancy; Pregnancy in Diabetics; Selective Serotonin Reuptake Inhibitors; Weight Loss	2003
[What effect does losing weight have on hypertension?]. MMW Fortschritte der Medizin, 2003, Jul-10, Volume: 145, Issue:27-28 Topics: Anti-Obesity Agents; Appetite Depressants; Body Mass Index; Clinical Trials as Topic; Contraindications; Cyclobutanes; Exercise; Humans; Hypertension; Lactones; Life Style; Lipase; Obesity; Orlistat; Risk Factors; Time Factors; Weight Loss	2003
Modest weight loss and reduction in waist circumference after medical treatment are associated with favorable changes in serum adipocytokines. Metabolism: clinical and experimental, 2004, Volume: 53, Issue:4 Topics: Abdomen; Adipocytes; Adult; Anti-Obesity Agents; Appetite Depressants; Body Constitution; Cyclobutanes; Cytokines; Female; Humans; Lactones; Obesity; Orlistat; Prospective Studies; Weight Loss	2004
[Pharmacotherapy of obesity]. Ugeskrift for laeger, 2004, Oct-18, Volume: 166, Issue:43 Topics: Anti-Obesity Agents; Appetite Depressants; Clinical Trials as Topic; Cyclobutanes; Evidence-Based Medicine; Humans; Lactones; Obesity; Obesity, Morbid; Orlistat; Treatment Outcome; Weight Loss	2004
[Obesity pharmacological treatment]. Revista clinica espanola, 2005, Volume: 205, Issue:4 Topics: Anti-Obesity Agents; Cyclobutanes; Humans; Lactones; Obesity; Orlistat	2005
New options for drug treatment of obesity in patients with Type 2 diabetes. Diabetic medicine : a journal of the British Diabetic Association, 2005, Volume: 22 Suppl 4 Topics: Anti-Obesity Agents; Appetite Depressants; Cannabinoids; Cyclobutanes; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Lactones; Male; Middle Aged; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant	2005
Trends in obesity and overweight-related office visits and drug prescriptions in Canada, 1998 to 2004. Obesity research, 2005, Volume: 13, Issue:11 Topics: Adult; Aged; Anti-Obesity Agents; Canada; Cyclobutanes; Drug Prescriptions; Female; Humans; Lactones; Male; Middle Aged; Obesity; Office Visits; Orlistat; Overweight; Prevalence	2005
Keeping weight-loss drugs in perspective. If you're dangerously overweight, diet pills may help--but not without major lifestyle changes. Harvard women's health watch, 2006, Volume: 13, Issue:8 Topics: Anti-Obesity Agents; Cyclobutanes; Eating; Female; Humans; Lactones; Obesity; Orlistat; Overweight; Weight Loss	2006
Baseline serum folate level may be a predictive factor of weight loss in a morbid-obesity-management programme. The British journal of nutrition, 2006, Volume: 96, Issue:5 Topics: Adolescent; Adult; Anti-Obesity Agents; Appetite Depressants; Biomarkers; Cyclobutanes; Eating; Female; Ferritins; Folic Acid; Humans; Lactones; Life Style; Male; Middle Aged; Obesity, Morbid; Orlistat; Prospective Studies; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Weight Loss	2006
Incorrect use of orlistat and sibutramine in clinical practice. European journal of clinical pharmacology, 2007, Volume: 63, Issue:2 Topics: Anti-Obesity Agents; Appetite Depressants; Contraindications; Cyclobutanes; Guideline Adherence; Humans; Lactones; Medication Errors; Obesity; Orlistat; Practice Patterns, Physicians'; Risk Factors; Surveys and Questionnaires; Sweden; Weight Loss	2007
Long-term persistence with orlistat and sibutramine in a population-based cohort. International journal of obesity (2005), 2007, Volume: 31, Issue:10 Topics: Adult; Anti-Obesity Agents; British Columbia; Cyclobutanes; Epidemiologic Methods; Female; Humans; Lactones; Male; Middle Aged; Obesity; Orlistat; Patient Compliance; Time Factors	2007
National trends in the use and costs of anti-obesity medications in England 1998-2005. Journal of public health (Oxford, England), 2007, Volume: 29, Issue:2 Topics: Anti-Obesity Agents; Cyclobutanes; Drug Costs; Drug Therapy; England; Humans; Lactones; Obesity; Orlistat; Prevalence	2007
Who will lose weight on sibutramine and orlistat? Psychological correlates for treatment success. Diabetes, obesity & metabolism, 2008, Volume: 10, Issue:6 Topics: Adolescent; Adult; Aged; Anti-Obesity Agents; Appetite; Appetite Depressants; Body Weight; Cyclobutanes; Diet, Reducing; Feeding Behavior; Female; Humans; Lactones; Male; Middle Aged; Obesity; Orlistat; Personality; Retrospective Studies; Self Disclosure; Treatment Outcome; Weight Loss	2008
The obesity pandemic--how did we get here? The Annals of pharmacotherapy, 2007, Volume: 41, Issue:9 Topics: Anti-Obesity Agents; Bariatric Surgery; Cyclobutanes; Disease Outbreaks; Humans; Lactones; Obesity; Orlistat; Pharmacists; Professional Role	2007
Anti-obesity drug use before professional treatment in Taiwan. Asia Pacific journal of clinical nutrition, 2007, Volume: 16, Issue:3 Topics: Adolescent; Adult; Age Distribution; Anti-Obesity Agents; Body Mass Index; Combined Modality Therapy; Confidence Intervals; Cross-Sectional Studies; Cyclobutanes; Dietary Supplements; Drug Utilization; Evidence-Based Medicine; Female; Humans; Lactones; Male; Middle Aged; Obesity; Odds Ratio; Orlistat; Outpatient Clinics, Hospital; Phytotherapy; Prevalence; Sex Distribution; Surveys and Questionnaires; Taiwan; Weight Loss	2007
[Pharmacotherapy for weight loss in patients with type 2 diabetes]. Ugeskrift for laeger, 2007, Aug-13, Volume: 169, Issue:33 Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Diabetes Mellitus, Type 2; Evidence-Based Medicine; Fluoxetine; Follow-Up Studies; Humans; Lactones; Obesity; Orlistat; Randomized Controlled Trials as Topic; Risk Factors; Weight Loss	2007
The safety profiles of orlistat and sibutramine: results of prescription-event monitoring studies in England. Obesity (Silver Spring, Md.), 2007, Volume: 15, Issue:11 Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Adult; Adverse Drug Reaction Reporting Systems; Anti-Obesity Agents; Appetite Depressants; Cohort Studies; Cyclobutanes; Drug Monitoring; England; Female; Humans; Lactones; Male; Middle Aged; Nausea; Obesity; Orlistat; Pregnancy; Pregnancy Outcome; Sweating; Treatment Outcome; Vomiting	2007
[Antiobesity drugs--new limitations]. Revue medicale suisse, 2007, Nov-28, Volume: 3, Issue:135 Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Depression; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Lactones; Obesity, Morbid; Orlistat; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Suicide; Weight Loss	2007
[Struggle about the best reducing diet, Fat gone by means of more fat?]. MMW Fortschritte der Medizin, 2004, Jan-15, Volume: 146, Issue:1-2 Topics: Adolescent; Adult; Anti-Obesity Agents; Antidepressive Agents; Appetite Depressants; Body Mass Index; Comorbidity; Cross-Over Studies; Cyclobutanes; Diet, Carbohydrate-Restricted; Diet, Reducing; Dietary Carbohydrates; Dietary Fats; Energy Intake; Female; Humans; Lactones; Lipase; Male; Mental Disorders; Middle Aged; Obesity; Orlistat; Randomized Controlled Trials as Topic; Sex Factors; Time Factors; Weight Loss	2004
[Pharmacological therapy of obesity]. Giornale italiano di cardiologia (2006), 2008, Volume: 9, Issue:4 Suppl 1 Topics: Anti-Obesity Agents; Appetite Depressants; Body Mass Index; Bradykinin; Cannabinoid Receptor Antagonists; Cannabinoids; Cyclobutanes; Diabetes Mellitus, Type 2; Double-Blind Method; Economics, Pharmaceutical; Humans; Lactones; Lipase; Meta-Analysis as Topic; Obesity; Orlistat; Piperidines; Practice Guidelines as Topic; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Risk Factors; Time Factors; Weight Loss	2008
Fundamentals of cardiometabolic risk factor reduction: achieving and maintaining weight loss with pharmacotherapy or bariatric surgery. Clinical cornerstone, 2008, Volume: 9, Issue:1 Topics: Anti-Obesity Agents; Bariatric Surgery; Cannabinoid Receptor Modulators; Cardiovascular Diseases; Cyclobutanes; Diabetes Mellitus, Type 2; Humans; Lactones; Obesity; Orlistat; Risk Factors; Weight Loss	2008
The endocannabinoid system as a target for obesity treatment. Clinical cornerstone, 2008, Volume: 9, Issue:1 Topics: Amides; Anti-Obesity Agents; Cannabinoid Receptor Modulators; Cyclobutanes; Depression; Endocannabinoids; Humans; Lactones; Life Style; Metabolic Syndrome; Obesity; Orlistat; Piperidines; Pyrazoles; Pyridines; Rimonabant; Risk	2008
Treating obesity in the family practice setting. Postgraduate medicine, 2001, Volume: 109, Issue:6 Suppl Topics: Anti-Obesity Agents; Appetite Depressants; Body Mass Index; Cardiovascular Diseases; Cyclobutanes; Humans; Lactones; Obesity; Orlistat; Primary Health Care; Risk Assessment; Weight Loss	2001
Exploring synergies in the treatment of obesity. Postgraduate medicine, 2001, Volume: 109, Issue:6 Suppl Topics: Anti-Obesity Agents; Appetite Depressants; Behavior Therapy; Body Mass Index; Combined Modality Therapy; Cyclobutanes; Diet, Reducing; Exercise; Feeding Behavior; Humans; Lactones; Life Style; Nutritional Status; Obesity; Orlistat; Weight Loss	2001
Emerging strategies for weight management. Summary. Postgraduate medicine, 2001, Volume: 109, Issue:6 Suppl Topics: Anti-Obesity Agents; Appetite Depressants; Body Mass Index; Cyclobutanes; Feeding Behavior; Health Behavior; Humans; Lactones; Life Style; Nutritional Status; Obesity; Orlistat; Weight Loss	2001
What extent of weight loss can benefit the health-related quality of life in motivated obese Chinese? Asia Pacific journal of clinical nutrition, 2009, Volume: 18, Issue:3 Topics: Adolescent; Adult; Anti-Obesity Agents; Appetite Depressants; Combined Modality Therapy; Cyclobutanes; Diet, Reducing; Female; Health Status; Humans; Lactones; Male; Middle Aged; Motivation; Obesity; Orlistat; Quality of Life; Sex Characteristics; Taiwan; Weight Loss; Young Adult	2009
Rise in antiobesity drug prescribing for children and adolescents in the UK: a population-based study. British journal of clinical pharmacology, 2009, Volume: 68, Issue:6 Topics: Adolescent; Age Distribution; Anti-Obesity Agents; Child; Child, Preschool; Cyclobutanes; Drug Prescriptions; Drug Utilization; Drugs, Investigational; Female; Humans; Infant; Lactones; Legislation, Drug; Male; Obesity; Orlistat; Practice Patterns, Physicians'; Risk Factors; Time Factors; Treatment Outcome; United Kingdom	2009
Use of psychotropic drugs and analgesics among users of antiobesity drugs--a population based study. Pharmacoepidemiology and drug safety, 2010, Volume: 19, Issue:3 Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Analgesics; Anti-Obesity Agents; Child; Cyclobutanes; Databases, Factual; Drug Interactions; Female; Humans; Lactones; Male; Middle Aged; Norway; Orlistat; Piperidines; Practice Patterns, Physicians'; Psychotropic Drugs; Pyrazoles; Rimonabant; Sex Factors; Young Adult	2010
Fat attack. Scientific American, 2010, Volume: 303, Issue:3 Topics: Anti-Obesity Agents; Appetite Depressants; Benzazepines; Brain; Cyclobutanes; Humans; Lactones; Obesity; Orlistat	2010
Weight loss maintenance. American family physician, 2010, Sep-15, Volume: 82, Issue:6 Topics: Anti-Obesity Agents; Cyclobutanes; Diet, Reducing; Exercise; Gastric Bypass; Humans; Lactones; Obesity; Orlistat; Weight Loss	2010
The effect of weight loss and treatment with metformin on serum vaspin levels in women with polycystic ovary syndrome. Endocrine journal, 2011, Volume: 58, Issue:4 Topics: Adolescent; Adult; Body Mass Index; Cyclobutanes; Diet, Reducing; Female; Humans; Lactones; Metformin; Orlistat; Overweight; Polycystic Ovary Syndrome; Serpins; Weight Loss	2011
[Long-term effects of weight-reducing drugs in hypertensive patients--a survey of a Cochrane review]. Ugeskrift for laeger, 2011, Feb-21, Volume: 173, Issue:8 Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Blood Pressure; Cardiovascular Diseases; Cyclobutanes; Evidence-Based Medicine; Humans; Hypertension; Lactones; Obesity; Orlistat; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Time Factors; Treatment Outcome; Weight Loss	2011
Comparative efficiency and safety of pharmacological approaches to the management of obesity. Diabetes care, 2011, Volume: 34 Suppl 2 Topics: Anti-Obesity Agents; Bridged Bicyclo Compounds, Heterocyclic; Cyclobutanes; Humans; Lactones; Obesity; Orlistat	2011
Adherence to weight loss medications; post-marketing study from HMO pharmacy data of one million individuals. Diabetes research and clinical practice, 2011, Volume: 94, Issue:2 Topics: Adult; Analysis of Variance; Anti-Obesity Agents; Body Mass Index; Comorbidity; Cyclobutanes; Diabetes Mellitus; Female; Health Care Surveys; Health Maintenance Organizations; Humans; Insurance, Pharmaceutical Services; Israel; Lactones; Logistic Models; Male; Medication Adherence; Middle Aged; Obesity; Odds Ratio; Orlistat; Product Surveillance, Postmarketing; Registries; Time Factors; Treatment Outcome; Weight Loss; Young Adult	2011
Cost-effectiveness of pharmacotherapy to reduce obesity. PloS one, 2011, Volume: 6, Issue:10 Topics: Anti-Obesity Agents; Australia; Cost-Benefit Analysis; Cyclobutanes; Drug Costs; Humans; Lactones; Obesity; Orlistat; Treatment Failure	2011
Evaluation of mutagenic effect of two antiobesity drugs on mice's genetic materials. Drug and chemical toxicology, 2012, Volume: 35, Issue:4 Topics: Animals; Anti-Obesity Agents; Bone Marrow Cells; Chromosome Aberrations; Cyclobutanes; Cytogenetic Analysis; Dose-Response Relationship, Drug; Lactones; Mice; Micronucleus Tests; Mutagenicity Tests; Mutagens; Orlistat	2012
FPIN’s clinical inquiries. Medications for weight loss in patients with type 2 diabetes mellitus. American family physician, 2012, Mar-15, Volume: 85, Issue:6 Topics: Anti-Obesity Agents; Cyclobutanes; Diabetes Mellitus, Type 2; Fluoxetine; Fructose; Humans; Lactones; Orlistat; Selective Serotonin Reuptake Inhibitors; Topiramate	2012
Assessment of maximum weight change and duration of therapeutic effect for non-surgical treatment of obesity using an exponential model. Eating and weight disorders : EWD, 2012, Volume: 17, Issue:4 Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Benzazepines; Body Mass Index; Body Weight; Cyclobutanes; Diet Therapy; Female; Humans; Lactones; Male; Models, Theoretical; Obesity; Orlistat; Sensitivity and Specificity; Treatment Outcome; Weight Loss	2012
Time series analyses of the effect of FDA communications on use of prescription weight loss medications. Obesity (Silver Spring, Md.), 2014, Volume: 22, Issue:3 Topics: Adolescent; Adult; Aged; Anti-Obesity Agents; Appetite Depressants; Cohort Studies; Cyclobutanes; Drug Utilization; Female; Humans; Lactones; Male; Middle Aged; Obesity; Orlistat; Phentermine; United States; United States Food and Drug Administration; Weight Loss; Young Adult	2014
The effectiveness of pharmaceutical interventions for obesity: weight loss with orlistat and sibutramine in a United Kingdom population-based cohort. British journal of clinical pharmacology, 2015, Volume: 79, Issue:6 Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Body Mass Index; Case-Control Studies; Cyclobutanes; Databases, Factual; Female; Humans; Lactones; Linear Models; Longitudinal Studies; Male; Middle Aged; Obesity; Orlistat; Primary Health Care; Time Factors; Treatment Outcome; United Kingdom; Weight Gain; Weight Loss	2015
The effect of sibutramine prescribing in routine clinical practice on cardiovascular outcomes: a cohort study in the United Kingdom. International journal of obesity (2005), 2015, Volume: 39, Issue:9 Topics: Anti-Obesity Agents; Appetite Depressants; Cohort Studies; Contraindications; Cyclobutanes; Female; Humans; Lactones; Male; Middle Aged; Myocardial Infarction; Obesity; Orlistat; Patient Safety; Patient Selection; Practice Patterns, Physicians'; Proportional Hazards Models; Risk Factors; Stroke; United Kingdom	2015
Positive association between the changes in chemerin and adiponectin levels after weight reduction. Endocrine research, 2017, Volume: 42, Issue:4 Topics: Adiponectin; Adult; Anti-Obesity Agents; Appetite Depressants; Biomarkers; Body Mass Index; Chemokines; Combined Modality Therapy; Cyclobutanes; Diet, Reducing; Exercise; Female; Healthy Lifestyle; Humans; Insulin Resistance; Intercellular Signaling Peptides and Proteins; Lactones; Male; Middle Aged; Obesity; Orlistat; Overweight; Waist Circumference; Weight Loss	2017
Treatment with Antiobesity Drugs in Weight Regain After Bariatric Surgery: a Retrospective Cohort Study. Obesity surgery, 2023, Volume: 33, Issue:9 Topics: Aged; Anti-Obesity Agents; Bariatric Surgery; Female; Humans; Male; Middle Aged; Obesity, Morbid; Orlistat; Retrospective Studies; Topiramate; Weight Gain; Weight Loss	2023